Malaria vaccine dosing study for people in rural villages
Part of Infections clinical trials.
This study tests different doses and forms of a malaria vaccine to see which works best and is safest. It may help protect you from malaria for a full year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must live in one of the study villages for the next 12 months.
- You must be 14 to 60 years old.
- You must provide written permission (or have a parent/guardian do so if you are under 18).
- You cannot be pregnant, planning to get pregnant within a month of vaccination, or breastfeeding.
- You must not have had any serious reaction to the study vaccine before.
- You must not have received any other malaria vaccine in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving a malaria vaccine and a malaria drug together to whole villages in Bangladesh can help stop the spread of malaria and protect the entire community. It is open to nearly everyone living in selected villages, including children and adults.
This study looks at how well the R21/Matrix-M malaria vaccine works in real-life settings for children under 5. If your child is eligible for the vaccine and has a fever, they may be able to join and help us understand the vaccine's impact.
This trial tests a seasonal vaccination schedule with the R21 malaria vaccine to help eliminate malaria in your community. It may be a good fit if you are looking for a way to protect yourself or your child from malaria during peak transmission seasons.
This study compares two experimental malaria vaccines to see how safe they are and how well they protect adults. It may help future malaria prevention, and you would be closely monitored, including a malaria “challenge” test if you qualify.
This trial tests a new malaria vaccine in healthy children. It aims to see if the vaccine is safe and how well it works in children who have had their regular childhood shots.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.